| Ident. | Authors (with country if any) | Title |
|---|
| 000008 (2010) |
P. Roll [Allemagne] ; A. Rubbert-Roth [Allemagne] ; H.-P. Tony [Allemagne] | Tocilizumab |
| 000025 (2014) |
Shuji Ohta [Japon] ; Tomomi Tsuru [Japon] ; Kimio Terao [Japon] ; Seiji Mogi [Japon] ; Midori Suzaki [Japon] ; Eisuke Shono [Japon] ; Yoshimasa Ishida [Japon] ; Eriko Tarumi [Japon] ; Masato Imai [Japon] | Mechanism‐based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study) |
| 000154 (2011) |
Atsushi Kaneko [Japon] ; Daihei Kida [Japon] ; Kiwamu Saito [Japon] ; Masami Tsukamoto [Japon] ; Tomotaro Sato [Japon] | Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI |
| 000382 (2013) |
M. J. Lim ; S. H. Park [Corée du Sud] ; S.-C. Shim ; H. J. Baek ; D.-H. Yoo ; H. A. Kim ; S. K. Lee ; Y. J. Lee [Corée du Sud] ; Y. E. Park ; H.-S. Cha ; W. Park ; Y.-W. Song [Corée du Sud] | AB0562 A double-blind, placebo-controlled, multicenter trial of tocilizumab in moderate to severe active RA patients with inadequate response to methotrexate in korean population |
| 000383 (2013) |
M. C. Vieira [États-Unis] ; G. V. Wallenstein [États-Unis] ; J. D. Bradley [États-Unis] ; D. Gruben [États-Unis] ; T. Koncz [États-Unis] ; S. H. Zwillich [États-Unis] ; J. P. Jansen [États-Unis] | FRI0185 Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs - a network meta-analysis |
| 000461 (2011) |
Alberto Migliore [Italie, Espagne] ; Emanuele Bizzi [Italie] ; Serena Broccoli [Italie] ; Bruno Laganà [Italie] | Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator |
| 000466 (2009) |
Taio Naniwa [Japon] ; Maiko Watanabe [Japon] ; Shogo Banno [Japon] ; Tomoyo Maeda [Japon] | Adding low dose tacrolimus in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies |
| 000473 (2013) |
E. Nasonov ; E. Panasyuk ; E. Shikina [Russie] ; T. Plaksina ; A. Dmitrieva ; L. Troegubova [Russie] | AB0525 Local open-label multicenter study to evaluate the quality of life in patients with moderate to severe active rheumatoid arthritis and an inadequate response to DMARDS when adding tocilizumab |
| 000479 (2013) |
M. Lisbona ; J. Maymo ; A. Pàmies ; J. Ares [Espagne] ; A. Solano [Espagne] ; M. Almirall ; S. Sanchez ; J. Carbonell | AB0542 Early reduction in synovitis and bone EDEMA evaluated by MRI in tocilizumab-treated RA patients with inadequate response to anti-TNF |
| 000604 (2013) |
M. Hochberg [États-Unis] ; S. Berry [États-Unis] ; K. Broglio [États-Unis] ; A. Nadkarni [États-Unis] ; L. Rosenblatt [États-Unis] ; D. Trivedi [États-Unis] ; T. Hebden [États-Unis] | AB0552 Relative efficacy and tolerability of intravenous and subcutaneous abatacept compared with tumor necrosis factor inhibitors in rheumatoid arthritis patients with an inadequate response to conventional disease-modifying antirheumatic drugs |
| 000660 (2013) |
M. C. Vieira [États-Unis] ; G. Wallenstein ; J. Bradley ; D. Gruben ; T. Koncz [États-Unis] ; S. H. Zwillich ; J. P. Jansen [États-Unis] | SAT0115 Tofacitinib Versus Biologic Treatments in Patients with Active Rheumatoid Arthritis Who have had an Inadequate Response to Tumour Necrosis Factor Inhibitors - A Network Meta-Analysis |
| 000704 (2013) |
S. Martin-Du-Pan ; D. Neto ; P. Zufferey [Suisse] ; A. Ciurea ; H. Ziswiler [Suisse] ; C. Gabay ; A. Finckh | SAT0104 Comparison of Drug Discontinuation to Inefficacy and Adverse Events Between Anti-Tnf Agents and ‘Non-Anti-Tnf Biologic Agents’ in Anti-Tnf Inadequate Responder Rheumatoid Arthritis Patients |
| 000722 (2013) |
Geoffrey Littlejohn [Australie, États-Unis] ; Lynden Roberts [Australie] ; Mark Arnold [Australie] ; Paul Bird [Australie] ; Simon Burnet [Australie] ; Julien De Jager [Australie] ; Hedley Griffiths [Australie] ; Dave Nicholls [Australie] ; James Scott [Australie] ; Jane Zochling [Australie] ; Kathleen E. Tymms [Australie] | A multi‐center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control |
| 000741 (2013) |
E. Keystone [Canada] ; S. B. Cohen [États-Unis] ; P. Emery [Royaume-Uni] ; J. M. Kremer [États-Unis] ; M. Dougados [France] ; J. E. Loveless ; C. Chung [États-Unis] ; P. Wong [États-Unis] ; P. B. Lehane [Royaume-Uni] ; H. Tyrrell [Royaume-Uni] | AB0526 Sustained efficacy responses and a consistent safety profile with rituximab repeat treatment over 5 years in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors in the reflex study |
| 000791 (2013) |
L. Xie ; M. C. Genovese [États-Unis] ; B. Zhu ; E. Edson-Heredia ; S. Banerjee | SAT0137 Early Clinical Improvements (Week 4) Predict Subsequent Clinical Response with Ixekizumab in Rheumatoid Arthritis Patients with Inadequate Response to tnf Inhibitors |
| 000804 (2013) |
T. Takeuchi [Japon] ; Y. Kaneko [Japon] ; T. Atsumi ; Y. Tanaka ; M. Inoh ; H. Kobayashi [Japon] ; K. Amano ; M. Miyata ; Y. Murakawa ; T. Fujii ; A. Kawakami ; H. Yamanaka ; K. Yamamoto ; N. Miyasaka [Japon] ; T. Mimori | OP0040 Adding Tocilizumab or Switching to Tocilizumab Monotherapy in RA Patients with Inadequate Response to Methotrexate: 24-Week Results from a Randomized Controlled Study (Surprise Study) |
| 000828 (2013) |
E. Keystone [Canada] ; D. Weber [Canada] ; J. Xiong [Canada] ; Y. Sun [Canada] ; A. Grant [Canada] | FRI0226 Rituximab versus abatacept in rheumatoid arthritis patients with an inadequate response to prior biologic therapy: a retrospective single-center study |
| 000850 (2013) |
A. Östör [Royaume-Uni] ; J. A. Román Ivorra [Espagne] ; J. Wollenhaupt [Allemagne] ; C. Mpofu [Suisse] ; C. Bernasconi [Suisse] ; J. Sibilia [France] ; V. Bykerk [États-Unis, Canada] | FRI0179 Comparison of tocilizumab as monotherapy or in combination with non-biological disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) and an inadequate response to anti-TNF agents |
| 000943 (2013) |
C. Codreanu ; I. Ancuta ; R. Ionescu [Roumanie] | FRI0220 Sustained clinical efficacy after multiple courses of rituximab in rheumatoid arthritis patients with inadequate response to tumour necrosis factor inhibitors: 2-year data from the repeat (repeated courses in routine clinical practice) study |
| 000B44 (2012) |
W. Rigby [États-Unis] ; H. Tony [Allemagne] ; K. Oelke [États-Unis] ; B. Combe [France] ; A. Laster [États-Unis] ; C. A. Von Muhlen [Brésil] ; E. Fisheleva [Royaume-Uni] ; C. Martin [Royaume-Uni] ; H. Travers [Royaume-Uni] ; W. Dummer [États-Unis] | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial |
| 000C53 (2013) |
T. Matsubara ; H. Inoue ; M. Iwahashi ; A. Yamazaki ; T. Takeuchi [Japon] | THU0125 A multi-center, double-dummy, double-blind study of subcutaneous (SC) abatacept (ABA) compared with intraveneous (IV) ABA in japanese rheumatoid arthritis patients with inadequate response to methotrexate |
